Skip to main content
GHRS
NASDAQ Life Sciences

1.175亿美元承销发行以每股18.00美元定价，低于当前市场价

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$19.71
Mkt Cap
$1.231B
52W Low
$8.75
52W High
$24.66
Market data snapshot near publication time

summarizeSummary

GH Research PLC宣布以每股18.00美元的价格发行6,527,779股普通股的承销发行，产生约1.175亿美元的总收入。这次发行很重要，代表着公司当前市值的约9.5%，并且以低于当前19.71美元的股票价格定价。这种显著的稀释对现有股东可能会在短期内对股票价格施加下行压力。所筹集的资金将用于资助临床阶段生物制药公司的运营和开发工作。交易者将关注股票对稀释性定价和预计于2026年4月30日完成发行的反应。

在该公告发布时，GHRS的交易价格为$19.71，交易所为NASDAQ，所属行业为Life Sciences，市值约为$12.3亿。 52周交易区间为$8.75至$24.66。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed GHRS - Latest Insights

GHRS
Apr 29, 2026, 8:26 AM EDT
Filing Type: 424B5
Importance Score:
8
GH Research Prices $117.5M Public Offering at $18.00 Per Share to Fund Clinical Development
Sentiment: Neutral
View Wiseek Article
GHRS
Apr 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
$117.5M Underwritten Offering Priced at $18.00 Per Share, Below Current Market
Sentiment: Negative
View Wiseek Article
GHRS
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
White House Executive Order to Accelerate Psychedelic Mental Health Treatments, Bolstering GH Research
Sentiment: Positive
View Wiseek Article
GHRS
Mar 25, 2026, 11:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
GH Research's GH001 Efficacy Holds Strong Regardless of Prior Treatment Failures, New Data Shows
Sentiment: Positive
View Wiseek Article
GHRS
Mar 05, 2026, 7:08 AM EST
Source: Dow Jones Newswires
Importance Score:
8
GH Research's 2025 Loss Per Share Widens to 79 Cents
Sentiment: Negative
View Wiseek Article
GHRS
Mar 05, 2026, 7:04 AM EST
Filing Type: 6-K
Importance Score:
7
GH Research Reports Full Year 2025 Results, Strong Cash Position, and Targets 2026 Phase 3 Initiation for GH001
Sentiment: Neutral
View Wiseek Article
GHRS
Jan 15, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
GH Research Reports Strong Phase 2b/2a Data for GH001 in Treatment-Resistant Depression, Postpartum Depression, and Bipolar II
Sentiment: Positive
View Wiseek Article
GHRS
Jan 13, 2026, 7:15 AM EST
Filing Type: 6-K
Importance Score:
9
GH Research's GH001 Shows Significant Efficacy and Tolerability in Phase 2b TRD Trial
Sentiment: Positive
View Wiseek Article
GHRS
Jan 08, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8
GH Research Reports Positive Phase 2b TRD and Phase 2a Bipolar II Depression Trial Results for GH001
Sentiment: Positive
View Wiseek Article
GHRS
Jan 05, 2026, 7:20 AM EST
Filing Type: 6-K
Importance Score:
9
FDA Lifts Clinical Hold on GH001, Paving Way for Global Phase 3 in Treatment-Resistant Depression
Sentiment: Positive
View Wiseek Article